Production of a Single‐chain Variable Fragment Antibody Recognizing Type III Mutant Epidermal Growth Factor Receptor
- 1 October 2000
- journal article
- Published by Wiley in Japanese Journal of Cancer Research
- Vol. 91 (10) , 1035-1043
- https://doi.org/10.1111/j.1349-7006.2000.tb00882.x
Abstract
The type III deletion mutant of the epidermal growth factor receptor (EGFR) is a potential target in diagnostic and therapeutic approaches for those glioblastomas characterized by its expression. We previously raised a mouse monoclonal antibody, 3C10 (IgG2b) specifically recognizing this mutant EGFR. In this study, a single‐chain variable fragment (scFv) antibody was produced. Partial determination of its N‐terminal amino acid sequence and preparation of adequate primers for variable heavy chain (VH) and variable light chain (VL) genes were performed to allow cloning by means of reverse transcriptase‐polymerase chain reaction. The genes cloned were assembled with a linker, (Gly4Ser)3, and ligated into a bacterial expression vector to express the scFv as cytoplasmic inclusion bodies. After appropriate refolding, the antibody activity of the VH‐VL scFv was examined in an enzyme‐linked immunosorbent assay. 3C10 scFv showed a selective reactivity with the mutant peptide, similarly to the parental 3C10 antibody. A mouse transfectant expressing the type III mutant EGFR and a glioblastoma with type III deletion‐mutant EGFR were positively stained by immunofluorescence. By Biacore analysis, the affinity (KA) of the parental 3C10 for the mutant peptide was 9.7x107M‐1, while that of 3C10 scFv was 2.45‐2.48x107M‐1, being approximately 4‐fold weaker. The results together suggested that the scFv antibody retained the appropriate structure to recognize a conformational epitope of the mutant receptor, similarly to the parental antibody.Keywords
This publication has 21 references indexed in Scilit:
- Suppression of metastasis formation by a recombinant single chain antibody-toxin targeted to full-length and oncogenic variant EGF receptorsOncogene, 1999
- Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: Targeting with a single chain antibody variable domain isolated by phage displayProceedings of the National Academy of Sciences, 1996
- Specific targeting of a mutant, activated egf receptor found in glioblastoma using a monoclonal antibodyInternational Journal of Cancer, 1995
- Structural alterations of the epidermal growth factor receptor gene in human gliomas.Proceedings of the National Academy of Sciences, 1992
- Biosynthetic antibody binding sites: Development of a single-chain Fv model based on antidinitrophenol IgA myeloma MOPC 315Protein Journal, 1991
- Deletion-mutant epidermal growth factor receptor in human gliomas: Effect of type II mutation on receptor functionBiochemical and Biophysical Research Communications, 1991
- [3] Protein engineering of single-chain Fv analogs and fusion proteinsPublished by Elsevier ,1991
- A Deletion Mutation within the Ligand Binding Domain Is Responsible for Activation of Epidermal Growth Factor Receptor Gene in Human Brain TumorsJapanese Journal of Cancer Research, 1990
- Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma.Proceedings of the National Academy of Sciences, 1990
- Prediction of the Secondary Structure of Proteins from their Amino Acid SequencePublished by Wiley ,1979